<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156034</url>
  </required_header>
  <id_info>
    <org_study_id>SRKMD-2021</org_study_id>
    <secondary_id>2021-003991-15</secondary_id>
    <nct_id>NCT05156034</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarkana Pharma Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarkana Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of&#xD;
      SRK-001 in Healthy Participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 21, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)</measure>
    <time_frame>Baseline through final follow-up at approximately Day 155</time_frame>
    <description>Number of participants with one or more TEAEs and SAEs will be reported in the adverse events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve During a Dosing Interval (AUC0-tau) at Steady State</measure>
    <time_frame>Day 1 (End of the infusion [EOI]) up to Day 155 post EOI</time_frame>
    <description>Pharmacokinetics (PK) after single and multiple IV dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2)</measure>
    <time_frame>Day 1 (EOI) up to Day 155 post EOI</time_frame>
    <description>PK after single and multiple IV dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations at End of Infusion (Cmax)</measure>
    <time_frame>Day 1 (EOI) up to Day 155 post EOI</time_frame>
    <description>PK after single and multiple IV dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations at End of Dosing Interval (Ctrough)</measure>
    <time_frame>Day 1 (EOI) up to Day 155 post EOI</time_frame>
    <description>PK after single and multiple IV dosing.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>SRK-001- Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRK-001- Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRK-001- Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV SRK-001 Q2W for 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRK-001</intervention_name>
    <description>Participants will receive IV doses of SRK-001.</description>
    <arm_group_label>SRK-001- Dose 1</arm_group_label>
    <arm_group_label>SRK-001- Dose 2</arm_group_label>
    <arm_group_label>SRK-001- Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive IV doses of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have clinical chemistry laboratory values within the acceptable range&#xD;
             for the population, as per the investigator judgment&#xD;
&#xD;
          -  Body mass index of 18 to 32 kilogram (kg)/ square meter (m^2)&#xD;
&#xD;
          -  Healthy male participants&#xD;
&#xD;
               1. Nonvasectomized male participants must agree to abstain from sexual intercourse&#xD;
                  or use a condom as well as 1 additional highly effective method of contraception&#xD;
                  (less than [&lt;]1 percent [%] failure rate) or effective method of contraception&#xD;
                  with all sexual partners of childbearing potential during the study and for 90&#xD;
                  days following the last dose of study intervention&#xD;
&#xD;
               2. Must agree not to donate sperm from start of dosing until 90 days beyond the last&#xD;
                  dose of study intervention&#xD;
&#xD;
               3. No restrictions are required for a vasectomized male&#xD;
&#xD;
          -  Healthy female participants of childbearing potential who have a fertile male sexual&#xD;
             partner must be willing and able to practice effective contraception from screening to&#xD;
             90 days after the last dose of the study intervention. Sexually active participants&#xD;
             must use a combination of 2 of the following methods of contraception, including at&#xD;
             least 1 so-called 'barrier' method:&#xD;
&#xD;
               1. hormonal contraceptives (oral, transdermal patches, vaginal, or injectable)&#xD;
&#xD;
               2. intrauterine device with or without hormones&#xD;
&#xD;
               3. condom, diaphragm, or cervical cap ('barrier' method)&#xD;
&#xD;
               4. sexual abstinence, and&#xD;
&#xD;
               5. vasectomized partner&#xD;
&#xD;
          -  Has been fully vaccinated for COVID-19 with the last dose of vaccine administered at&#xD;
             least 3 weeks prior to study intervention administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For at least 30 days prior to randomization, participants must have no symptoms and/or&#xD;
             signs of confirmed or suspected infection (including COVID-19) and must have completed&#xD;
             any appropriate anti-infective treatment&#xD;
&#xD;
          -  Have any concomitant systemic disorder, human immunodeficiency virus (HIV) infection,&#xD;
             current infection with hepatitis B virus (HBV) (that is, positive for hepatitis B&#xD;
             surface antigen and/or polymerase chain reaction positive for HBV DNA, hepatitis C&#xD;
             virus (HCV) (that is, positive for HCV ribo nucleic acid[RNA]), symptomatic herpes&#xD;
             zoster within 6 months prior to screening, an eye condition currently requiring&#xD;
             treatment for trauma, contact allergy, postsurgical, or conjunctivitis that may&#xD;
             interfere with eye evaluations, active or latent tuberculosis (TB)&#xD;
&#xD;
          -  Are currently enrolled in or have participated in greater than (&gt;) 4 clinical trials&#xD;
             in the past 12 months involving a study intervention or off-label use of a drug or&#xD;
             device, or any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study or have received a. any nonbiologic IP within 30&#xD;
             days or 5 half-lives (whichever is longer) of their baseline (Day -1) visit, or b. any&#xD;
             biologic IP within 3 months or 5 half-lives (whichever is longer) of their baseline&#xD;
             (Day -1) visit&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) or 14&#xD;
             units per week (females) or are unwilling to stop alcohol consumption from 48 hours&#xD;
             prior to each dosing (1 unit = 12 ounce [oz] or 360 milliliter [mL] of beer; 5 oz or&#xD;
             150 mL of wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Drug abuse in the past 12 months and/or show positive findings on drug screening&#xD;
             unless they were prescribed by a physician (for example, benzodiazepines)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarkana Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>3176517036</phone>
    <email>choruspharma@lists.lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <phone>+31 50 4022 524</phone>
      <email>hadisalah@prahs.com</email>
    </contact>
    <investigator>
      <last_name>Salah Hadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

